14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CCCC vs OTLK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over C4 Therapeutics, Inc. (CCCC) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CCCC carries a Unified Composite Score of 55.0/100 (HOLD) at $2.69 (N/M Forward P/E, -315.9% operating margin), whereas OTLK carries 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin).
Composite vs. Pillar Nuance: While CCCC currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. OTLK 48.6/100 HOLD), OTLK captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (4781.8% vs. -315.9% operating margin) and revenue trajectory (-99.4% vs. -24.6% YoY).
Technical & Structure Timing Caution: CCCC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.0); meanwhile OTLK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $363.7M market capitalization and -315.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
OTLK Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $107.1M market capitalization and 4781.8% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CCCC vs OTLK Key Questions & Quantitative Answers
As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over C4 Therapeutics, Inc. (CCCC) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CCCC carries a Unified Composite Score of 55.0/100 (HOLD) at $2.69 (N/M Forward P/E, -315.9% operating margin), whereas OTLK carries 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin). Composite vs. Pillar Nuance: While CCCC currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. OTLK 48.6/100 HOLD), OTLK captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (4781.8% vs. -315.9% operating margin) and revenue trajectory (-99.4% vs. -24.6% YoY). Technical & Structure Timing Caution: CCCC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.0); meanwhile OTLK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CCCC leads the Growth & Scale pillar: CCCC posts -24.6% YoY revenue growth and +0.0% YoY earnings growth on $32M TTM revenue (88.8% gross margin, -315.9% operating margin), compared with OTLK at -99.4% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 4781.8% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), CCCC cumulative revenue shifted -20.0% while OTLK shifted N/A. In operating R&D and SG&A reinvestment, CCCC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OTLK.
OTLK screens cheaper on headline valuation multiples. CCCC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 12.0x EV/Revenue (unreported FCF margin), whereas OTLK trades at 2.9x Forward P/E, 2.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CCCC (-47.6% ROE) versus OTLK (-3.6% ROE) capital efficiency.
In options market volatility and institutional positioning, CCCC carries 79.8% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.43β · 67% Vol realized risk). By comparison, OTLK carries 181.3% implied volatility (55th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 79% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.